Format

Send to

Choose Destination
See comment in PubMed Commons below
J Hematol Oncol. 2011 Dec 21;4:53. doi: 10.1186/1756-8722-4-53.

Pharmacological basis and clinical evidence of dabigatran therapy.

Author information

  • 1Service of Hematology, Hospital Nuestra Señora de Sonsoles, Ávila, Spain. santiredondo@hotmail.com

Abstract

Dabigatran is an emerging oral anticoagulant which is a direct inhibitor of thrombin activity. It has been approved in the European Union and the United States of America for the prevention of thrombosis after major orthopedic surgery. It has also been approved by the American Food and Drug Administration and the European Medicines Agency for the prevention of stroke in chronic atrial fibrillation. Dabigatran provides a stable anticoagulation effect without any need to perform periodical laboratory controls. Of note, there is a growing amount of clinical evidence which shows its safety and efficacy. For these reasons, dabigatran may suppose a revolution in oral anticoagulation. However, two important limitations remain. First, it is contraindicated in patients with end-stage renal disease. Second, there is no evidence of the prevention of thrombosis in mechanical heart valves.

PMID:
22189016
PMCID:
PMC3262761
DOI:
10.1186/1756-8722-4-53
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Support Center